Seaport Therapeutics presents additional Phase 1 pharmacokinetic data for GlyphAgo at ECNP

Seaport Therapeutics (SPTX) presented additional pharmacokinetic data from a Phase 1 clinical trial of GlyphAgo at the 39th European College of Neuropsychopharmacology (ECNP) Congress.